A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)
This Phase 3 placebo-controlled study is planned to further investigate the efficacy,
safety, and tolerability of apraglutide in the overall SBS-IF (short bowel syndrome
associated with intestinal failure) population during 24 weeks of study treatment. It is
expected...
Age: 18 years - 66+
Gender: All
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome
(DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD)
and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12
weeks...
Age: 12 years - 66+
Gender: All
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
This is a multicenter screening study to characterize the prevalence of the KIT D816V
mutation in participants with suspected clonal mast cell disease.
Age: 18 years - 66+
Gender: All
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy
and safety of paltusotine treatment vs placebo as well as the long-term safety of
paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine
tumors. ...
Age: 18 years - 66+
Gender: All
Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19
The study is conducted in New York, New York at The Cohen Center for Recovery from
Complex Chronic Illness at Mount Sinai.
This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled
clinical trial of sirolimus (also known as rapamycin) in adu...
Age: 18 years - 66+
Gender: All
Atomoxetine in Melanocortin Obesity Syndrome
This is a phase 2 randomized placebo-controlled crossover trial to determine the safety
and efficacy of atomoxetine for treating obesity caused by loss-of-function variants in
the melanocortin-4 receptor (MC4R), the most common cause of genetic obesity disorders.
Ato...
Age: 6 years - 66+
Gender: All
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
This will be a pilot multi-arm clinical trial investigating the feasibility of 6 weeks of Lumbrokinase (LK) as an intervention in three clinical cohorts:
Long Covid (LC)
Post-treatment Lyme disease syndrome (PTLDS)
Myalgic encephalomyelitis/chronic fatigue syndrome (ME...
Age: 18 years - 66+
Gender: All
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
This is a phase 2, randomized, multiple-dose, placebo-controlled study designed to
evaluate the safety, efficacy, and pharmacokinetics (PK) of CSL889 (human hemopexin) when
given intravenously (IV) to adults and adolescents with sickle cell disease (SCD)
experiencing...
Age: 12 years - 66+
Gender: All
Immunologic Basis of Food Protein-Induced Enterocolitis Syndrome
This is a phase I multicenter clinical trial that aims to find the optimal dose for
conducting a novel low-dose, multi-day oral food challenge (OFC) protocol for diagnosing
food protein-induced enterocolitis syndrome (FPIES). Individuals ages 1-60 years with a
histor...
Age: 1 year - 60 years
Gender: All
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
This is a Phase 1/2, first in human, open-label, dose-escalation study to evaluate the
safety, tolerability, and clinical activity of a single dose of JAG201 administered via
intracerebroventricular (ICV) injection in pediatric and adult participants with SHANK3
hapl...
Age: 2 - 9 years
Gender: All
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus
Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in
Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell
Transplantation
Age: 18 years - 66+
Gender: All
A Prospective Research Investigation of Ischemia Using MCG
PRISM is a prospective, pilot research study that aims to systematically characterize the
usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of
myocardial ischemia and infarction status.
Age: 18 years - 66+
Gender: All
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells).
The purpose of this study is to assess the safety of venetoclax in combination with
obinutuzumab or acalabrutinib in the treatment of CLL. Adverse events and change in
disease act...
Age: 18 years - 66+
Gender: All
RECOVER-SLEEP: Platform Protocol
The platform protocol is designed to be flexible so that it is suitable for a range of
study settings and intervention types. Therefore, the platform protocol provides a
general protocol structure that can be shared by multiple interventions and allows
comparative an...
Age: 18 years - 66+
Gender: All
MCG Discovery Study in Emergency Departments
This prospective discovery study is designed to demonstrate the feasibility of using an
unshielded, mobile MCG device in an Emergency Department (ED) setting. The main question
it aims to answer is whether interpretable data can be reliably collected as part of an
ED...
Age: 18 years - 66+
Gender: All
A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants
The purpose of this study is to evaluate the efficacy and safety of Luspatercept when
administered at the maximum approved dose in low-risk Myelodysplastic Syndrome
participants who require red blood cell transfusions.
Age: 18 years - 66+
Gender: All
Persuasive Health Communication Intervention for HIV/HCV
A major impediment to emergency department (ED)-based HIV/HCV screening success is that
often ED patients at risk for, or later diagnosed with, HIV and HCV decline testing. In
this R01 project, the research team will assess how well a promising, easy-to-use,
one-time...
Age: 18 years - 66+
Gender: All
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel)
work together in treating patients with Richter's syndrome that has come back (recurrent)
or does not respond to treatment (refractory). Richter's syndrome occurs when chronic
lym...
Age: 18 years - 66+
Gender: All
A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)
GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of
GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible
after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after
the fir...
Age: 18 - 85 years
Gender: All
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
Aortix is a circulatory support device for chronic heart failure patients on medical
management who have been hospitalized for acute decompensated heart failure (ADHF) and
have persistent congestion despite usual medical therapy.
Eligible ADHF patients with diureti...
Age: 21 years - 66+
Gender: All